CN-122005601-A - Use of vitamin B12

Abstract

The invention relates to the technical field of vitamin B12, and discloses application of vitamin B12, wherein the application comprises the application of vitamin B12 in preparing a medicament for treating glycogen storage disease. The vitamin B12 can be applied to the preparation of medicines for treating glycogen storage disease, and can treat glycogen storage disease.

Inventors

• TIAN DONG
• LI WEI
• LI TENG
• ZHU XUEYU

Assignees

• 天津医科大学
• 清华大学

Dates

Publication Date

20260512

Application Date

20241112

Claims (10)

1. 1. Use of vitamin B12, characterized in that the use comprises the use of vitamin B12 in the preparation of a medicament for the treatment of glycogen storage disease.
2. 2. The use according to claim 1, wherein vitamin B12 is replaced by a vitamin B12 derivative, a precursor that generates vitamin B12, a probiotic enriched with vitamin B12, a pharmaceutically acceptable salt of vitamin B12.
3. 3. The use according to claim 1, characterized in that the daily dose of vitamin B12 is in an amount of 2 x 10 -3 nmol-0.2nmol.
4. 4. Use of vitamin B12 and N-acetylcysteine for the preparation of a medicament for the treatment of glycogen storage disease.
5. 5. Use according to claim 4, characterized in that vitamin B12 is replaced by a vitamin B12 derivative, a precursor which generates vitamin B12, a probiotic enriched with vitamin B12, a pharmaceutically acceptable salt of vitamin B12.
6. 6. Use according to claim 4, characterized in that the daily dose of vitamin B12 is in the amount of 0.2 x 10 -3 nmol-0.01nmol and the daily dose of n-acetylcysteine is in the amount of 2 x 10 -3 mmol-0.01mmol.
7. 7. A medicament for treating glycogen storage disease, comprising vitamin B12 and N-acetylcysteine.
8. 8. The medicament according to claim 7, wherein the medicament is in the form of an injection, a tablet, a capsule, a dispersion, a rapidly disintegrating dosage form, an effervescent tablet dosage form, an ointment dosage form, a gel dosage form or a transdermal sustained release dosage form.
9. 9. The medicament of claim 7, wherein vitamin B12 is replaced by a vitamin B12 derivative, a precursor that produces vitamin B12, a probiotic enriched with vitamin B12, a pharmaceutically acceptable salt of vitamin B12.
10. 10. The medicament of claim 7, wherein the glycogen storage disease comprises GSD 0 glycogen storage disease, GSD I glycogen storage disease, GSD II glycogen storage disease, GSD III glycogen storage disease, GSD IV glycogen storage disease, GSD V glycogen storage disease, GSD VI glycogen storage disease, GSD VII glycogen storage disease, GSD IX glycogen storage disease, GSD X glycogen storage disease, GSD XI glycogen storage disease, GSD XII glycogen storage disease, GSD XIII glycogen storage disease, GSD XIV glycogen storage disease, GSD XV glycogen storage disease, fanconi-biker syndrome, PGK deficiency, and ravude disease.

Description

Use of vitamin B12 Technical Field The invention relates to the technical field of vitamin B12, in particular to application of vitamin B12. Background Glucose metabolism provides a large number of ATP for cellular vital activity by coupling glycolysis, tricarboxylic acid cycle and oxidative phosphorylation. While in vivo excess glucose is stored mainly in the form of glycogen in the liver and muscle and in small amounts in brain tissue. Glucose and glycogen are converted to each other by glycogenogenesis and glycogenolysis, respectively, thereby acting to stabilize blood glucose and to meet normal cellular energy requirements. Glucose metabolism disorders are associated with a variety of human diseases including cardiovascular disease, diabetes, and glycogen storage disease, among others. Glycogen storage disease is a group of metabolic diseases caused by monogenic defects, caused by biochemical defects in different metabolic steps in glycogenogenesis, glycogenolysis or glycolysis. The onset age is wide, and can occur from neonates to adults. The affected organs include the liver, muscles, kidneys and nervous system. Typical symptoms include hypoglycemia, exercise intolerance, growth retardation, confusion, hepatomegaly, and the like. Based on the different genes affected and their expression in different tissues, at least 15 types of glycogen storage disease (some of which contain multiple subclasses) have been clinically identified, as well as several atypical glycogen storage diseases such as Fanconi-Bickel syndrome (Fanconi syndrome), PGK deficiency and laval disease (Lafora disease). Currently, there is no effective treatment for any type of glycogen storage disease. Patients with glycogen accumulation are clinically treated mainly by diet management. In certain types of glycogen storage diseases, corn starch and high protein may be used to provide energy, as in liver type glycogen storage diseases, metabolic imbalance is generally avoided by providing sufficient nutrition (e.g., frequency, diet, and type of diet). Although diet management can alleviate glycogen storage disease symptoms to some extent, it has severe effects on the quality of life of patients due to strict requirements on diet frequency and variety. In addition, type II glycogen storage disease has precedent Enzyme Replacement Therapy (ERT). While some severely ill glycogen accumulating patients may require liver or other organ transplants. Enzyme replacement therapy or organ transplantation, however, places a great economic burden on the patient. Disclosure of Invention In order to solve the technical problems, the invention provides application of vitamin B12, and the vitamin B12 can be applied to preparing medicines for treating glycogen storage diseases, and can treat the glycogen storage diseases. The present invention provides the use of vitamin B12, comprising the use of vitamin B12 in the manufacture of a medicament for the treatment of glycogen storage disease. Further, the vitamin B12 is replaced by vitamin B12 derivatives, precursors that can produce vitamin B12, probiotics that are rich in vitamin B12, and pharmaceutically acceptable salts of vitamin B12. Further, the daily dose of vitamin B12 is in the range of 2X 10 -3 nmol to 0.2nmol. Further, the daily dose of vitamin B12 is in the range of 2X 10 -2 nmol to 0.1nmol. The invention also provides application of vitamin B12 and N-acetylcysteine in preparing medicines for treating glycogen storage disease. Further, the vitamin B12 is replaced by vitamin B12 derivatives, precursors that can produce vitamin B12, probiotics that are rich in vitamin B12, and pharmaceutically acceptable salts of vitamin B12. Further, the daily dose of vitamin B12 is 0.2X10 -3 nmol to 0.01nmol and the daily dose of N-acetylcysteine is 2X 10 -3 mmol to 0.01mmol. Further, the daily dose of vitamin B12 was 2X 10 -3 nmol and the daily dose of N-acetylcysteine was 0.01mmol. The invention also provides a medicament for treating glycogen storage disease, which is prepared from vitamin B12 and N-acetylcysteine. Further, the medicine dosage forms are injection, tablet, capsule, dispersing agent, fast disintegrating dosage form, effervescent tablet dosage form, ointment dosage form, gel dosage form or transdermal sustained release agent dosage form. Further, the vitamin B12 is replaced by vitamin B12 derivatives, precursors that can produce vitamin B12, probiotics that are rich in vitamin B12, and pharmaceutically acceptable salts of vitamin B12. Further, the glycogen storage disease includes GSD 0 type glycogen storage disease, GSD I type glycogen storage disease, GSD II type glycogen storage disease, GSD III type glycogen storage disease, GSD IV type glycogen storage disease, GSD V type glycogen storage disease, GSD VI type glycogen storage disease, GSD VII type glycogen storage disease, GSD IX type glycogen storage disease, GSD X type glycogen storage disease, GSD XI type glycogen storage disease, GSD XI